137 related articles for article (PubMed ID: 36993198)
1. Refining the serum miR-371a-3p test for viable germ cell tumor detection: identification and definition of an indeterminate range.
Lafin J; Scarpini C; Amini A; Konneh B; Howard J; Gerald T; Nuno M; Piao J; Savelyeva A; Wang Z; Gagan J; Jia L; Lewis C; Murray S; Sawa Y; Margulis V; Woldu S; Strand D; Coleman N; Amatruda J; Frazier L; Murray M; Bagrodia A
Res Sq; 2023 Mar; ():. PubMed ID: 36993198
[TBL] [Abstract][Full Text] [Related]
2. Refining the serum miR-371a-3p test for viable germ cell tumor detection.
Lafin JT; Scarpini CG; Amini A; Konneh B; Howard JM; Gerald T; Nuno M; Piao J; Savelyeva A; Wang Z; Gagan J; Jia L; Lewis CM; Murray S; Sawa YC; Margulis V; Woldu SL; Strand DW; Coleman N; Amatruda JF; Frazier AL; Murray MJ; Bagrodia A
Sci Rep; 2023 Jun; 13(1):10558. PubMed ID: 37386046
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of miR-371a-3p to predict viable germ cell tumor in patients with pure seminoma receiving retroperitoneal lymph node dissection.
Konneh B; Lafin JT; Howard J; Gerald T; Amini A; Savelyeva A; Woldu SL; Lewis CM; Jia L; Margulis V; Coleman N; Scarpini C; Frazier AL; Murray MJ; Amatruda JF; Bagrodia A
Andrology; 2023 May; 11(4):634-640. PubMed ID: 36254623
[TBL] [Abstract][Full Text] [Related]
4. Analytical Validation and Performance Characteristics of Molecular Serum Biomarkers, miR-371a-3p and miR-372-3p, for Male Germ Cell Tumors, in a Clinical Laboratory Setting.
Ye F; Feldman DR; Valentino A; So R; Bromberg M; Khan S; Funt SA; Sheinfeld J; Solit DB; Pessin MS; Peerschke EI
J Mol Diagn; 2022 Aug; 24(8):867-877. PubMed ID: 35934321
[TBL] [Abstract][Full Text] [Related]
5. Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR; Abe D; Wong D; Singla N; Savelyeva A; Chertack N; Woldu SL; Lotan Y; Mauck R; Ouyang D; Meng X; Lewis CM; Majmudar K; Jia L; Kapur P; Xu L; Frazier AL; Margulis V; Strand DW; Coleman N; Murray MJ; Amatruda JF; Lafin JT; Bagrodia A
J Urol; 2021 Jan; 205(1):137-144. PubMed ID: 32856980
[TBL] [Abstract][Full Text] [Related]
6. The combination of microRNA-371a-3p and 375-5p can distinguish viable germ cell tumor and teratoma from necrosis in postchemotherapy retroperitoneal lymph node dissection specimens.
Kremer L; von Brandenstein M; Wittersheim M; Koeditz B; Paffenholz P; Hellmich M; Pfister D; Heidenreich A; Nestler T
Transl Androl Urol; 2021 Apr; 10(4):1647-1655. PubMed ID: 33968653
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA miR-371a-3p in serum of patients with germ cell tumours: evaluations for establishing a serum biomarker.
Spiekermann M; Belge G; Winter N; Ikogho R; Balks T; Bullerdiek J; Dieckmann KP
Andrology; 2015 Jan; 3(1):78-84. PubMed ID: 25187505
[TBL] [Abstract][Full Text] [Related]
8. High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours.
Dieckmann KP; Hennig F; Anheuser P; Gehrckens R; Viehweger F; Wülfing C; Belge G
Urol Int; 2021; 105(1-2):21-26. PubMed ID: 33049748
[TBL] [Abstract][Full Text] [Related]
9. Accurate primary germ cell cancer diagnosis using serum based microRNA detection (ampTSmiR test).
van Agthoven T; Looijenga LHJ
Oncotarget; 2017 Aug; 8(35):58037-58049. PubMed ID: 28938535
[TBL] [Abstract][Full Text] [Related]
10. Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours.
Dieckmann KP; Radtke A; Spiekermann M; Balks T; Matthies C; Becker P; Ruf C; Oing C; Oechsle K; Bokemeyer C; Hammel J; Melchior S; Wosniok W; Belge G
Eur Urol; 2017 Feb; 71(2):213-220. PubMed ID: 27495845
[TBL] [Abstract][Full Text] [Related]
11. Graded expression of microRNA-371a-3p in tumor tissues, contralateral testes, and in serum of patients with testicular germ cell tumor.
Belge G; Hennig F; Dumlupinar C; Grobelny F; Junker K; Radtke A; Dieckmann KP
Oncotarget; 2020 Apr; 11(16):1462-1473. PubMed ID: 32363003
[No Abstract] [Full Text] [Related]
12. A Multi-institutional Pooled Analysis Demonstrates That Circulating miR-371a-3p Alone is Sufficient for Testicular Malignant Germ Cell Tumor Diagnosis.
Piao J; Lafin JT; Scarpini CG; Nuño MM; Syring I; Dieckmann KP; Belge G; Ellinger J; Amatruda JF; Bagrodia A; Coleman N; Krailo MD; Frazier AL; Murray MJ
Clin Genitourin Cancer; 2021 Dec; 19(6):469-479. PubMed ID: 34629299
[TBL] [Abstract][Full Text] [Related]
13. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Fankhauser CD; Christiansen AJ; Rothermundt C; Cathomas R; Wettstein MS; Grossmann NC; Grogg JB; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Moch H; Beyer J; Hermanns T
Br J Cancer; 2022 May; 126(8):1140-1144. PubMed ID: 34912073
[TBL] [Abstract][Full Text] [Related]
14. Editorial by Bendu K. Konneh, John T. Lafin and Aditya Bagrodia on pp. 341-342 of this issue: MicroRNA-371a-3p as a blood-based biomarker in testis cancer.
Ahmadi H; Jang TL; Daneshmand S; Ghodoussipour S
Asian J Urol; 2021 Oct; 8(4):400-406. PubMed ID: 34765447
[TBL] [Abstract][Full Text] [Related]
15. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.
Leão R; van Agthoven T; Figueiredo A; Jewett MAS; Fadaak K; Sweet J; Ahmad AE; Anson-Cartwright L; Chung P; Hansen A; Warde P; Castelo-Branco P; O'Malley M; Bedard PL; Looijenga LHJ; Hamilton RJ
J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847
[TBL] [Abstract][Full Text] [Related]
16. Cellular origin of microRNA-371a-3p in healthy males based on systematic urogenital tract tissue evaluation.
Boellaard WPA; Gillis AJM; van Leenders GJLH; Stoop H; van Agthoven T; Dorssers LCJ; Dinkelman-Smit M; Boormans JL; Looijenga LHJ
Andrology; 2019 Jul; 7(4):463-468. PubMed ID: 30786164
[TBL] [Abstract][Full Text] [Related]
17. Can germ cell neoplasia in situ be diagnosed by measuring serum levels of microRNA371a-3p?
Radtke A; Cremers JF; Kliesch S; Riek S; Junker K; Mohamed SA; Anheuser P; Belge G; Dieckmann KP
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2383-2392. PubMed ID: 28819887
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of circulating miR-371a-3p for the management of patients with intracranial malignant germ cell tumors.
Murray MJ; Ajithkumar T; Harris F; Williams RM; Jalloh I; Cross J; Ronghe M; Ward D; Scarpini CG; Nicholson JC; Coleman N
Neurooncol Adv; 2020; 2(1):vdaa048. PubMed ID: 32642701
[TBL] [Abstract][Full Text] [Related]
19. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.
Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G
J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280
[TBL] [Abstract][Full Text] [Related]
20. Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence.
Christiansen AJ; Lobo J; Fankhauser CD; Rothermundt C; Cathomas R; Batavia AA; Grogg JB; Templeton AJ; Hirschi-Blickenstorfer A; Lorch A; Gillessen S; Moch H; Beyer J; Hermanns T
Front Oncol; 2022; 12():1056823. PubMed ID: 36568207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
